The origins of ovarian cancer: Hurdles and progress

Women's Oncology Review

Volumn 2, Issue 3, 2002, Pages 261-268

  Drapkin, Ronny ^a   Hecht, Jonathan ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; COMPLEMENTARY DNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR;

CANCER INHIBITION; CANCER MODEL; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DNA MICROARRAY; EARLY CANCER; EARLY DIAGNOSIS; ENDOMETRIOSIS; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC SUSCEPTIBILITY; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; MALIGNANT TRANSFORMATION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MENSTRUAL IRREGULARITY; MICROSATELLITE INSTABILITY; MUELLERIAN DUCT; ONCOGENE; ORAL CONTRACEPTION; OVARIECTOMY; OVARY CANCER; OVARY FOLLICLE DEVELOPMENT; OVULATION INHIBITION; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0036709363     PISSN: 14733404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47
2. Cannistra SA. Cancer of the ovary. N Engl J Med 1993;329:1550-9
3. Tresserra F, Grases PJ, Labastida R, Ubeda A. Histological features of the contralateral ovary in patients with unilateral ovarian cancer: a case control study. Gynecol Oncol 1998;71:437-41
4. Sherman ME, Lee JS, Burks RT, et al. Histopathologic features of ovaries at increased risk for carcinoma. A case-control analysis. Int J Gynecol Pathol 1999;18:151-7
5. Werness BA, Afify AM, Bielat KL, et al. Altered surface and cyst epithelium of ovaries removed prophylactically from women with a family history of ovarian cancer. Hum Pathol 1999;30:151-7
6. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993;9:138-41
7. Scully RE. Early de novo ovarian cancer and cancer developing in benign ovarian lesions. Int J Gynaecol Obstet 1995;49(Suppl.):S9-15
8. Scully RE. Pathology of ovarian cancer precursors. J Cell Biochem 1995;23(Suppl.):208-18
9. Scully R, Young R, Clement P. Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament. Third Series Fascicle 23, Washington, DC: Armed Forces Institute of Pathology, 1998
10. Plaxe SC, Deligdisch L, Dottino PR, Cohen CJ. Ovarian intraepithelial neoplasia demonstrated in patients with stage I ovarian carcinoma. Gynecol Oncol 1990;38:367-72
11. Mittal KR, Zeleniuch-Jacquotte A, Cooper JL, Demopoulos RI. Contralateral ovary in unilateral ovarian carcinoma: a search for preneoplastic lesions. Int J Gynecol Pathol 1993;12:59-63
12. Resta L, Russo S, Colucci GA, Prat J. Morphologic precursors of ovarian epithelial tumors. Obstet Gynecol 1993;82:181-6
13. Deligdisch L, Gil J, Kerner H, et al. Ovarian dysplasia in prophylactic oophorectomy specimens: cytogenetic and morphometric correlations. Cancer 1999;86:1544-50
14. Hutson R, Ramsdale J, Wells M. p53 protein expression in putative precursor lesions of epithelial ovarian cancer. Histopathology 1995;27:367-71
15. Pothuri B, Leitao M, Barakat R, et al. Genetic analysis of ovarian carcinoma histogenesis (abstract). Gynecol Oncol 2001;80:277
16. Silva EG, Kurman RJ, Russell P, Scully RE. Symposium: ovarian tumors of borderline malignancy. Int J Gynecol Pathol 1996;15:281-302
17. Bourne TH, Whitehead MI, Campbell S, et al. Ultrasound screening for familial ovarian cancer. Gynecol Oncol 1991;43:92-7
18. Kennedy AW, Hart WR. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma. Cancer 1996;78:278-86
19. Lee KR, Castrillon DH, Nucci MR. Pathologic findings in eight cases of ovarian serous borderline tumors, three with foci of serous carcinoma, that preceded death or morbidity from invasive carcinoma. Int J Gynecol Pathol 2001;20:329-34
20. Silva EG, Tornos CS, Malpica A, Gershenson DM. Ovarian serous neoplasms of low malignant potential associated with focal areas of serous carcinoma. Mod Pathol 1997;10:663-7
21. Ortiz BH, Ailawadi M, Colitti C, et al. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors. Cancer Res 2001;61:7264-7
22. Kupryjanczyk J, Bell DA, Dimeo D, et al. p53 gene analysis of ovarian borderline tumors and stage I carcinomas. Hum Pathol 1995;26:387-92
23. Cheng PC, Gosewehr JA, Kim TM, et al. Potential role of the inactivated X chromosome in ovarian epithelial tumor development. J Natl Cancer Inst 1996;88:510-8
24. Tangir J, Loughridge NS, Berkowitz RS, et al. Frequent microsatetlite instability in epithelial borderline ovarian tumors. Cancer Res 1996;56:2501-5
25. Halperin R, Zehavi S, Dar P, et al. Clinical and molecular comparison between borderline serous ovarian tumors and advanced serous papillary ovarian carcinomas. Eur J Gynaecol Oncol 2001;22:292-6
26. Wang VW, Bell DA, Berkowitz RS, Mok SC. Whole genome amplification and high-throughput allelotyping identified five distinct deletion regions on chromosomes 5 and 6 in microdissected early-stage ovarian tumors. Cancer Res 2001;61:4169-74
27. Lee KR, Scully RE. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'. Am J Surg Pathol 2000;24:1447-64
28. Hoerl HD, Hart WR. Primary ovarian mucinous cystadenocarcinomas: a clinicopathologic study of 49 cases with long-term follow-up. Am J Surg Pathol 1998;22:1449-62
29. Garrett AP, Lee KR, Colitti CR, et al. K-ras mutation may be an early event in mucinous ovarian tumorigenesis. Int J Gynecol Pathol 2001;20:244-51
30. Auersperg N, Wong AS, Choi KC, et al. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001;22:255-88
31. Auersperg N, Edelson MI, Mok SC, et al. The biology of ovarian cancer. Semin Oncol 1998;25:281-304
32. Lau KM, Mok SC, Ho SM. Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci USA 1999;96:5722-7
33. Mittal KR, Zeleniuch-Jacquotte A, Cooper JL, Demopoulos RI. Contralateral ovary in unilateral ovarian carcinoma: a search for preneoplastic lesions. Int J Gynecol Pathol 1993;12:59-63
34. Mittal K. Tumor markers in ovaries at risk of developing carcinoma. Int J Gynecol Pathol 2000;19:191-2
35. Karlan BY, Jones J, Greenwald M, Lagasse LD. Steroid hormone effects on the proliferation of human ovarian surface epithelium in vitro. Am J Obstet Gynecol 1995;173:97-104
36. McMeekin DS, Burger RA, Manetta A, et al. Endometrioid adenocarcinoma of the ovary and its relationship to endometriosis. Gynecol Oncol 1995;59:81-6
37. Sainz de la Cuesta R, Eichhorn JH, Rice LW, et al. Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol Oncol 1996;60:238-44
38. Rosenblatt KA, Thomas DB. Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer Epidemiol Biomarkers Prev 1996;5:933-5
39. Dubeau L. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Gynecol Oncol 1999;72:437-42
40. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1184-203
41. Nieto JJ, Crow J, Sundaresan M, et al. Ovarian epithelial dysplasia in relation to ovulation induction and nulliparity. Gynecol Oncol 2001;82:344-9
42. Fredrickson TN. Ovarian tumors of the hen. Environ Health Perspect 1987;73:35-51
43. Alison RH, Morgan KT. Ovarian neoplasms in F344 rats and B6C3F1 mice. Environ Health Perspect 1987;73:91-106
44. Behrman HR, Kodaman PH, Preston SL, Gao S. Oxidative stress and the ovary. J Soc Gynecol Investig 2001;8(Suppl. 1):S40-2
45. Murdoch WJ, Townsend RS, McDonnel AC. Ovulation-induced DNA damage in ovarian surface epithelial cells of ewes: prospective regulatory mechanisms of repair/survival and apoptosis. Biol Reprod 2001;65:1417-24
46. Auersperg N, Maines-Bandiera S, Dyck H. Phenotypic plasticity of ovarian surface epithelium. In: Sharp F, Blackett T, Leake R, Berek J, eds. Ovarian Cancer, vol. 4. Cambridge, UK: Lippincott Williams & Wilkins, 1996: 3-18
47. Berchuck A, Kohler MF, Marks JR, et al. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 1994;170:246-52
48. Tashiro H, Miyazaki K, Okamura H, et al. c-myc over-expression in human primary ovarian tumours: its relevance to tumour progression. Int J Cancer 1992;50:828-33
49. Enomoto T, Weghorst CM, Inoue M, et al. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 1991;139:777-85
50. Obata K, Morland SJ, Watson RH, et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 1998;58:2095-7
51. Wang K, Gan L, Jeffery E, et al. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene 1999;229:101-8
52. Schummer M, Ng WV, Bumgarner RE, et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 1999;238:375-85
53. Hough CD, Sherman-Baust CA, Pizer ES, et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 2000;60:6281-7
54. Hough CD, Cho KR, Zonderman AB, et al. Coordinately up-regulated genes in ovarian cancer. Cancer Res 2001;61:3869-76
55. Welsh JB, Sapinoso LM, Su AI, et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001;61:5974-8
56. Wong KK, Cheng RS, Mok SC. Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques 2001;30:670-5
57. Ono K, Tanaka T, Tsunoda T, et al. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 2000;60:5007-11
58. Shridhar V, Lee J, Pandita A, et al. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res 2001;61:5895-904
59. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7
60. Buckhaults P, Rago C, St Croix B, et al. Secreted and cell surface genes expressed in benign and malignant colorectal tumors. Cancer Res 2001;61:6996-7001
61. Sawiris G, Sherman-Baust C, Becker K, et al. Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer. Cancer Res 2002;62:2923-8
62. van Haaften-Day C, Shen Y, Xu F, et al. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer 2001;92:2837-44
63. Mok SC, Chao J, Skates S, et al. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 2001;93:1458-64
64. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002;287:1671-9
65. Bast Jr. RC, Xu F, Woolas RP, et al. Complementary and coordinate markers for detection of epithelial ovarian cancers. In: Sharp F, Mason P, Blackett T, Berek J, eds. Ovarian Cancer, vol. 3. London: Chapman & Hall, 1995:189-92
66. Wong AS, Kim SO, Leung PC, et al. Profiling of protein kinases in the neoplastic transformation of human ovarian surface epithelium. Gynecol Oncol 2001;82:305-11
67. Colgan TJ, Murphy J, Cole DE, et al. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 2001;25:1283-9
68. Lu KH, Garber JE, Cramer DW, et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 2000;18:2728-32
69. Colgan TJ, Murphy J, Cole DE, et al. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 2001;25:1283-9
70. Casey MJ, Bewtra C, Hoehne LL, et al. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds. Gynecol Oncol 2000;78:278-87
71. Deligdisch L, Gil J, Kerner H, et al. Ovarian dysplasia in prophylactic oophorectomy specimens: cytogenetic and morphometric correlations. Cancer 1999;86:1544-50
72. Stratton JF, Buckley CH, Lowe D, Ponder BA. Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. J Natl Cancer Inst 1999;91:626-8
73. Barakat RR, Federici MG, Saigo PE, et al. Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. Cancer 2000;89:383-90
74. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995;57:1457-62
75. Orsulic S, Soslow R, Vitale-Cross L, et al. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 2002;1:53-62